Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Total Marrow Irradiation and Myeloablative Chemotherapy Followed By Double Umbilical Cord Blood Transplantation In Patients With High Risk Hematological Malignancies

Next Previous
Trial Profile

Total Marrow Irradiation and Myeloablative Chemotherapy Followed By Double Umbilical Cord Blood Transplantation In Patients With High Risk Hematological Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin; Cyclophosphamide; Fludarabine; Mycophenolate mofetil
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 05 Dec 2017 Biomarkers information updated
  • 13 Aug 2012 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
  • 18 Dec 2009 Planned end date changed from 1 Sep 2012 to 1 Sep 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top